Superluminal Medicines
AI and structural biology for hard GPCR drug targets
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Superluminal Medicines is a Boston biotechnology company that combines AI/ML, protein dynamics, and structural biology to discover small-molecule drugs against difficult GPCR targets. Its lead program is a selective, biased MC4R agonist aimed at rare genetic forms of obesity and hypothalamic obesity, with a Phase 1 trial expected to begin by the end of 2026.
- Website
- superluminalrx.com
- Stage
- series-b+
- Founded
- 2022
- Location
- Boston, MA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Superluminal Hyperloop Platform — Structure-based AI discovery platform for GPCR therapeutics · Other